FST.L Regulatory News (FST)

1 February 2011

Toumaz Limited

Year end trading update

Toumaz Limited (AIM: TMZ, 'Toumaz', or 'the Group'), a pioneer in low cost, ultra low power wireless communications technology, has published a year end trading update for the 12 months to the end of December 2010.

The Group has traded in line with the Board's expectations and as at 31 December 2010 had a cash balance of approximately £2.75m. The Group's cash burn has been according to plan. 

Healthcare

The Group has developed and delivered its Sensium 'digital plaster' technology to its strategic partner on schedule. As part of the testing process of the complete system, user tests by nurses have been successfully completed. This will pave the way for our strategic partner to file with regulatory authorities and subsequently launch the product in 2011. 

Toumaz has also completed the design of the next generation integrated circuit of the Sensium chip which will help reduce cost and increase performance. The new chips are expected to be volume produced from mid 2011.

The research and development agreement with Quanta Computer Inc. has progressed well and has led to the prototype of a consumer-based connected activity monitor for Type 2 diabetics. Engineering samples for customers are expected at the end of the second quarter of 2011.

Consumer

Toumaz launched the XENIF multimedia chip in Q4 2001 and has started volume deliveries to its tier one customer. XENIF is an all-in-one DAB, Wi-Fi, baseband and application processor, which incorporates

licensed IP from Imagination Technologies Group PLC, capable of delivering internet- connected digital radio.

Separately, the Group has today announced that it has launched TELRAN, its ultra-low energy wireless radio System-on-Chip which addresses the wider low energy wireless communications market, with initial orders already taken by Toumaz.

The Group expects to publish its full year results in March 2011. 

Enquiries:

About Toumaz (www.toumaz.com)

Toumaz is pioneering low cost, ultra-low power wireless technologies for a wide range of markets including medical monitoring and internet-connected consumer devices.

Targeting the Healthcare market, Toumaz's licensable smart sensor interface and transceiver platform, Sensium, is a leader in real-time wireless monitoring of the body's vital signs. Sensium has the potential to transform medical monitoring and reduce the cost of healthcare by wirelessly connecting individuals to healthcare providers - simply, affordably and unobtrusively. For healthcare professionals, this creates new opportunities for pro-active monitoring and improved quality of care. For patients, it delivers new opportunities for lifestyle-compatible personalised healthcare.

Toumaz also uses its ultra low power expertise to design devices for wireless connectivity and internet-connected consumer products. Toumaz currently supplies FM/DAB radio chips and complete modules to leaders in the digital radio market, such as PURE. 

Toumaz is an AIM listed company (AIM: TMZ) with development centres in Oxford, UK and Taipei City, Taiwan.